Chronic
innate immune activation is a key hallmark of many neurological
diseases and is known to result in the upregulation of GPR84 in myeloid
cells (macrophages, microglia, and monocytes). As such, GPR84 can
potentially serve as a sensor of proinflammatory innate immune responses.
To assess the utility of GPR84 as an imaging biomarker, we synthesized
11
C-MGX-10S
and
11
C-MGX-11S
via
carbon-11 alkylation
for use as positron emission tomography (PET) tracers targeting this
receptor.
In vitro
experiments demonstrated significantly
higher binding of both radiotracers to hGPR84-HEK293 cells than that
of parental control HEK293 cells. Co-incubation with the GPR84 antagonist
GLPG1205 reduced the binding of both radiotracers by >90%, demonstrating
their high specificity for GPR84
in vitro
.
In vivo
assessment of each radiotracer
via
PET imaging of healthy mice illustrated the superior brain uptake
and pharmacokinetics of
11
C-MGX-10S
compared to
11
C-MGX-11S
. Subsequent
use of
11
C-MGX-10S
to image a
well-established mouse model of systemic and neuro-inflammation revealed
a high PET signal in affected tissues, including the brain, liver,
lung, and spleen.
In vivo
specificity of
11
C-MGX-10S
for GPR84 was confirmed by
the administration of GLPG1205 followed by radiotracer injection.
When compared with
11
C-DPA-713—an existing radiotracer
used to image innate immune activation in clinical research studies—
11
C-MGX-10S
has multiple advantages,
including its higher binding signal in inflamed tissues in the CNS
and periphery and low background signal in healthy saline-treated
subjects. The pronounced uptake of
11
C-MGX-10S
during inflammation, its high specificity for GPR84,
and suitable pharmacokinetics strongly support further investigation
of
11
C-MGX-10S
for imaging GPR84-positive
myeloid cells associated with innate immune activation in animal models
of inflammatory diseases and human neuropathology.